Cargando…

Patient-Reported Outcomes for Migraine in the US and Europe: Burden Associated with Multiple Preventive Treatment Failures

PURPOSE: To evaluate patient-reported outcomes (PROs) among patients with migraine, including those who were preventive-naïve and preventive-treated. METHODS: This was a point-in-time, real-world study of patients with migraine in the US and EU5 (France, Germany, Spain, Italy, and UK) and their phys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ford, Janet, Nichols, Russell M, Ye, Wenyu, Tockhorn-Heidenreich, Antje, Cotton, Sarah, Jackson, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286727/ https://www.ncbi.nlm.nih.gov/pubmed/34285524 http://dx.doi.org/10.2147/CEOR.S304158

Ejemplares similares

A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe
por: Ford, Janet H., et al.
Publicado: (2020)

Real-World Treatment Patterns and Outcomes Among Patients with Episodic Migraine in China: Results from the Adelphi Migraine Disease Specific Programme™
por: Zhao, Hongru, et al.
Publicado: (2023)

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
por: Reuter, Uwe, et al.
Publicado: (2021)

Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
por: Tepper, Stewart J., et al.
Publicado: (2022)

Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
por: Tepper, Stewart J., et al.
Publicado: (2022)

Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis
por: Ailani, Jessica, et al.
Publicado: (2022)

Efficacy of galcanezumab in patients with migraine and history of failure to 3–4 preventive medication categories: subgroup analysis from CONQUER study
por: Okonkwo, Rose, et al.
Publicado: (2021)

Discrete Choice Experiment to Understand Japanese Patients’ and Physicians’ Preferences for Preventive Treatments for Migraine
por: Seo, Jaein, et al.
Publicado: (2023)

Patient Perspectives and Experiences of Preventive Treatments and Self-Injectable Devices for Migraine: A Focus Group Study
por: Seo, Jaein, et al.
Publicado: (2021)

Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials
por: Ruff, D. D., et al.
Publicado: (2019)

Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
por: Citrome, Leslie, et al.
Publicado: (2021)

Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability
por: Ford, Janet H., et al.
Publicado: (2019)

A Real‐World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment
por: Lombard, Louise, et al.
Publicado: (2020)

Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme
por: Ueda, Kaname, et al.
Publicado: (2019)

Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme
por: Hirata, Koichi, et al.
Publicado: (2020)

Burden of Migraine in Europe Using Self-Reported Digital Diary Data from the Migraine Buddy© Application
por: Vo, Pamela, et al.
Publicado: (2018)

Burden and Quality of Life Among Female and Male Patients with Heart Failure in Europe: A Real-World Cross-Sectional Study
por: Fonseca, Ana Filipa, et al.
Publicado: (2021)

Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
por: Ford, Janet, et al.
Publicado: (2020)

Preventive treatment in migraine and the new US guidelines
por: Estemalik, E, et al.
Publicado: (2013)

The Humanistic and Economic Burden of Migraine in Europe: A Cross-Sectional Survey in Five Countries
por: Doane, Michael J., et al.
Publicado: (2020)

Unmet Needs in Japanese Patients Who Report Insufficient Efficacy with Triptans for Acute Treatment of Migraine: Retrospective Analysis of Real-World Data
por: Hirata, Koichi, et al.
Publicado: (2020)

The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal
por: Ornello, Raffaele, et al.
Publicado: (2019)

A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication
por: Lombard, Louise, et al.
Publicado: (2020)

Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study
por: Varnado, Oralee J, et al.
Publicado: (2022)

The global burden of migraine
por: Lipton, Richard B., et al.
Publicado: (2003)

New insights into the burden and costs of multiple sclerosis in Europe
por: Kobelt, Gisela, et al.
Publicado: (2017)

Association between sleep quality, migraine and migraine burden
por: Duan, Shaojie, et al.
Publicado: (2022)

Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine
por: Ford, Janet H., et al.
Publicado: (2023)

Patient Preferences for Biologic and Biosimilar Osteoporosis Treatments in Colombia
por: Graham-Clarke, Peita L, et al.
Publicado: (2020)

Associations between anxiety, depression with migraine, and migraine-related burdens
por: Duan, Shaojie, et al.
Publicado: (2023)

Caregivers of Patients with Heart Failure: Burden and the Determinants of Health-Related Quality of Life
por: Lahoz, Raquel, et al.
Publicado: (2021)

Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments
por: Nissan, George R., et al.
Publicado: (2022)

Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study
por: Pozo-Rosich, Patricia, et al.
Publicado: (2021)

Comparison of Lymphocyte Subset Populations in Children From South Africa, US and Europe
por: Payne, Helen, et al.
Publicado: (2020)

Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine
por: Buse, Dawn C., et al.
Publicado: (2020)

WITHDRAWAL—Administrative Duplicate Publication: The essential role of prevention in reducing the cancer burden in Europe: a commentary from Cancer Prevention Europe
por: Espina, Carolina, et al.
Publicado: (2019)

Burden of heart failure on caregivers in China: results from a cross-sectional survey
por: Jackson, James DS, et al.
Publicado: (2018)

My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed
por: Martelletti, Paolo, et al.
Publicado: (2018)

Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine
por: McAllister, Peter, et al.
Publicado: (2022)

Burden of heart failure on patients from China: results from a cross-sectional survey
por: Jackson, James DS, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7347n28s1slbgmadq2mrvp39pt